European regulators have agreed to review Clovis’ application to expand the use of its PARP inhibitor Rubraca in the region.
News
If you love a challenge, ENTER NOW
The PharmaTimes Marketer of the Year competition is celebrating it’s 25th anniversary and with a number companies including Sanofi, PharmaLex, Thornton & Ross, Roche, Bayer, Consilient Health, Cycle Pharmaceuticals and others already entered, it could just be the most exciting one to date.
Europe recalling some valsartan meds on safety fears
The European Medicines Agency is reviewing medicines containing valsartan supplied by a facility in China after a potentially cancer-causing impurity was detected.
Chinese firms eyeing up Sinclair Pharma
Shares in UK group Sinclair Pharma shot up nearly 40 percent after it confirmed interest from Chinese firms with regard to a possible take-over.
Eisai, Biogen’s Alzheimer’s candidate shows promise in PhII trial
At last some good news for Alzheimer’s research, as Eisai and Biogen’s experimental anti beta-amyloid therapy BAN2401 hit targets in a Phase II trial in patients with the disease.
Pfizer UK MD takes the helm at the ABPI
Erik Nordkamp, managing director of Pfizer UK, has been named as the new president of the Association of the British Pharmaceutical Industry (ABPI).
Data show Imnovid-based triple therapy PFS benefit in blood cancer
Celgene has presented Phase III data showing a significant progression-free survival (PFS) benefit in patients with multiple myeloma taking a triple combination therapy of Imnovid, Velcade and low-dose dexamethasone.
Survey shows public support for NHS tax rise
The vast majority of the public would be willing to accept tax increases to secure significant improvements in the NHS, finds a new poll by Ipos Mori commissioned by the NHS Confederation.
Final NICE no for BMS’ Opdivo in urothelial carcinoma
The National Institute for Health and Care Excellence has now issued final guidance rejecting NHS funding for use of Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).
UK’s genome sequencing project will hit 100,000 by year-end
Genomics England says the 100,000 Genomes Project is “well on track” to reach its target of sequencing 100,000 genomes by the end of this year.
MSD’s antiviral Prevymis fails to win NICE backing
MSD’s Prevymis has not won the support of NHS cost regulators for preventing cytomegalovirus (CMV) reactivation and disease in prone adults who have received an allogeneic haematopoietic stem cell transplant (HSCT).
FDA approves drug for excessive drooling
Merz Neuroscience’s Xeomin has become the first agent to be approved by the US Food and Drug Administration to treat excessive drooling.
RCGP urges parents to vaccinate children against measles
The Royal College of GPs is urging parents to get their children vaccinated in response to data highlighting a significant rise in cases in England.
Novartis to hand back rights to Aveo’s AV-380
Novartis is intending to hand back rights to Aveo Oncology’s experimental antibody AV-380, which it acquired in August 2015 in a deal valued at at least $326 million.
Cannabis-based meds beneficial for some conditions, finds UK review
The UK’s chief medical officer and advisor Professor Dame Sally Davies has concluded that there is evidence to show the therapeutic benefit of cannabis-based medicines for some conditions.
